21Jan 2024


  • Department of General Medicine, S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
  • Department of Anatomy, Pt. B. D. Sharma PGIMS Rohtak, Haryana, India.
  • Department of Medicine, Lady Hardinge Medical College, New Delhi, India.
Crossref Cited-by Linking logo
  • Abstract
  • Cite This Article as
  • Corresponding Author

Introduction: Multiple sclerosis, autoimmune disease of the central nervous system primarily affecting young adults. The number of individuals suffering from multiple sclerosis under the age of 18 is gradually increasing. Early interventions in the form of pharmacotherapy have proven to be beneficial in reducing the severity of disease and thereby preventing disability. Furthermore, cognitive impairment affecting working memory, attention, and other domains is concerning in children.

Methodology: We identified papers by searching various electronic databases (PubMed, Google Scholar, Europe PMC, Scopus, Web of Science). Search terms included: Pediatric multiple sclerosis OR pediatric MS AND interventions AND prognosis OR disease progression OR disability OR quality of life OR QoL. Papers were included in this review if they were published in English, referenced interventions and their effects on quality of life of the patients, and included pediatric-onset multiple sclerosis as a primary population. Results: Seventeen papers were identified via the literature search that addressed interventions made in the field of pediatric multiple sclerosis and their effects on the quality of life of the patients. The current study extracted data from a diverse range of articles focusing on various aspects of pediatric-onset multiple sclerosis (POMS) treatment, outcomes, and associated factors. The data provided valuable insights into the clinical characteristics, treatment approaches, and quality of life considerations for POMS patients.

Discussion: Interventions include first line drugs (interferon beta-1a and glatiramer acetate) and disease modifying therapies like fingolimod, teriflunomide, natalizumab and rituximab. Potential modifiable factors like breastfeeding, vitamin D levels, exercise and diet were identified. CSF Neurofilament levels and various inflammatory genes are helpful in diagnosis.

Conclusion: The data extraction from diverse studies on POMS shed light on various treatment approaches, disease progression markers and psychosocial factors. The findings underscore the importance of early intervention, tailored treatment strategies, and multidisciplinary care to enhance outcomes for pediatric MS patients.

[Shubham M.S, Anju Bala PhD, Anesh M.S, Ravneet Kaur M.S and Ruchi Das M.S (2024); INTERVENTIONS AFFECTING PROGNOSIS AND QUALITY OF LIFE IN PEDIATRIC MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW Int. J. of Adv. Res. (Jan). 330-342] (ISSN 2320-5407). www.journalijar.com

S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan


Article DOI: 10.21474/IJAR01/18126      
DOI URL: http://dx.doi.org/10.21474/IJAR01/18126